When are medical apps medical? Off-label use and the Food and Drug Administration

被引:3
作者
Krieger, William H. [1 ]
机构
[1] Univ Rhode Isl, Kingston, RI 02881 USA
来源
DIGITAL HEALTH | 2016年 / 2卷
关键词
Medical apps; Food and Drug Administration; mobile healthcare; off-label; conflict of interest;
D O I
10.1177/2055207616662782
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
People have a love/hate relationship with rapidly changing healthcare technology. While consumer demand for medical apps continues to grow as rapidly as does supply (there are over 100,000 health, wellness and medical applications, or 'apps' on the market), healthcare professionals and safety experts worry about the impact of these apps on the health consumer. In response to the rapidly growing mobile healthcare sector, the Food and Drug Administration has put forth guidelines to regulate 'mobile medical apps' (MMAs), those health-related apps that are (self) designated as medical devices. In this article, I argue that this decision, to only regulate apps that bill themselves as medical devices, will create a market for 'off-label' app use. Further, I will talk about the oft used analogy between off-label apps and off-label pharmaceuticals, showing that off-labeling apps will provide patients none of the benefits that come with a physician prescribing a drug off-label, while exposing the mobile healthcare consumer to significant risks that go significantly beyond those that we know of (and must accept) from prescription drugs. Recognizing that the Food and Drug Administration is not going to be able to significantly change its policies on oversight, I will suggest specific actions to at least mitigate some of the risks associated with off-label app use.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Off-Label Use of Spesolimab in Dermatology: A Systematic Review
    Sood, Siddhartha
    Waked, Jihad
    Merchant, Nabil
    Abduelmula, Abrahim
    Mufti, Asfandyar
    Yeung, Jensen
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2025,
  • [42] Use of off-label drugs in neonatal intensive care
    Sucasas Alonso, Andrea
    Avila-Alvarez, Alejandro
    Combarro Eiriz, Marina
    Martinez Roca, Cristina
    Yanez Gomez, Pedro
    Codias Lopez, Alejandra
    Fernandez Trisac, Jose Luis
    Pertega Diaz, Sonia
    ANALES DE PEDIATRIA, 2019, 91 (04): : 237 - 243
  • [43] Off-label use of ceftaroline fosamil: A systematic review
    Pani, Arianna
    Colombo, Fabrizio
    Agnelli, Francesca
    Frantellizzi, Viviana
    Baratta, Francesco
    Pastori, Daniele
    Scaglione, Francesco
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (05) : 562 - 571
  • [44] The Food and Drug Administration and pragmatic clinical trials of marketed medical products
    Anderson, Monique L.
    Griffin, Joseph
    Goldkind, Sara F.
    Zeitler, Emily P.
    Wing, Liz
    Al-Khatib, Sana M.
    Sherman, Rachel E.
    CLINICAL TRIALS, 2015, 12 (05) : 511 - 519
  • [45] Pattern and extent of off-label and unlicensed drug use in neonatal intensive care units in Iran
    Leila Kouti
    Maryam Aletayeb
    Seyyed Mohammad Hassan Aletayeb
    Amir Kamal Hardani
    Kaveh Eslami
    BMC Pediatrics, 19
  • [46] Off-Label and Unlicensed Medication Use and Associated Adverse Drug Events in a Pediatric Emergency Department
    Phan, Hanna
    Leder, Marc
    Fishley, Matthew
    Moeller, Matthew
    Nahata, Milap
    PEDIATRIC EMERGENCY CARE, 2010, 26 (06) : 424 - 430
  • [47] Pattern and extent of off-label and unlicensed drug use in neonatal intensive care units in Iran
    Kouti, Leila
    Aletayeb, Maryam
    Aletayeb, Seyyed Mohammad Hassan
    Hardani, Amir Kamal
    Eslami, Kaveh
    BMC PEDIATRICS, 2019, 19 (1)
  • [48] Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey
    Goran Palčevski
    Nataša Skočibušić
    Vera Vlahović-Palčevski
    European Journal of Clinical Pharmacology, 2012, 68 : 1073 - 1077
  • [49] Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey
    Palcevski, Goran
    Skocibusic, Natasa
    Vlahovic-Palcevski, Vera
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (07) : 1073 - 1077
  • [50] Paediatric drug use with focus on off-label prescriptions in Swedish outpatient care - a nationwide study
    Olsson, J.
    Kimland, E.
    Pettersson, S.
    Odlind, V.
    ACTA PAEDIATRICA, 2011, 100 (09) : 1272 - 1275